atai Life Sciences (NASDAQ:ATAI) (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for mental health disorders. Leveraging advances in neuroscience, chemistry and digital technologies, atai is advancing a diversified pipeline of product candidates designed to address conditions such as depression, anxiety, post-traumatic stress disorder (PTSD), substance use disorders and other neuropsychiatric indications.
The company operates a portfolio model in which it incubates and invests in subsidiary and partner companies, each dedicated to a specific therapeutic approach. atai’s pipeline includes small molecules, psychedelic compounds (including proprietary derivatives of psilocybin, DMT, ibogaine and ketamine) and digital therapeutics. Notable programs encompass ROL-101 for anxiety-related disorders, ROL-308 for treatment-resistant depression and other next-generation neuropharmaceuticals, as well as collaborative initiatives in precision psychiatry and biomarker development.
Founded in 2018 by entrepreneur Christian Angermayer, atai Life Sciences maintains its global headquarters in Berlin with additional offices in New York and London. The company has established preclinical and clinical partnerships across Europe and North America, enabling multi-site trials and regulatory interactions with agencies such as the U.S. Food and Drug Administration and the European Medicines Agency. Strategic alliances with research institutions and contract development organizations support atai’s goal of accelerating its programs toward regulatory approval.
atai’s leadership team comprises experienced executives and renowned scientists in neuroscience and drug development. Christian Angermayer serves as founder and executive chair, while an executive management team with backgrounds in biotech innovation, clinical operations and corporate strategy oversees day-to-day operations. Scientific and clinical advisory boards include leading experts in psychedelics research and psychiatric medicine, guiding the company’s progress toward new treatment paradigms in mental healthcare.
